"The U.S. Department of Health and Human Services today launched an annual challenge designed to identify and honor clinicians and health care teams that have helped their patients control high blood pressure and prevent heart attacks and strokes."...
Patients, especially those with evidence of coronary artery disease, should be warned against interruption or discontinuation of Sectral (acebutolol) therapy without a physician's supervision. Although cardiac failure rarely occurs in properly selected patients, those being treated with β-adrenergic blocking agents should be advised to consult a physician if they develop signs or symptoms suggestive of impending CHF, or unexplained respiratory symptoms.
Patients should also be warned of possible severe hypertensive reactions from concomitant use of a-adrenergic stimulants, such as the nasal decongestants commonly used in OTC cold preparations and nasal drops.
Last reviewed on RxList: 9/19/2007
This monograph has been modified to include the generic and brand name in many instances.
Additional Sectral Information
Sectral - User Reviews
Sectral User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
Get tips on handling your hypertension.